MorphoSys Swings To FY20 Profit

MorphoSys AG (MOR) reported full-year 2020 net profit of 97.9 million euros or 2.97 euro per share, compared to a loss of 103.0 million euros or 3.26 euros per share in the prior year.

Earnings before interest and taxes were 27.4 million euros, compared to a EBIT loss of 107.9 million euros in the previous year.

Group revenues were 327.7 million euros, up from 71.8 million euros in the prior year.

Monjuvi (tafasitamab-cxix) product sales totaled 18.5 million euros, while royalties on net sales of Tremfya amounted to 42.5 million euros.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT